Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy.
AUTOR(ES)
Gao, G P
RESUMO
Recombinant adenoviruses with E1 sequences deleted efficiently transfer genes into a wide variety of target cells. Antigen- and nonantigen-specific responses to the therapy lead to toxicity, loss of transgene expression, and difficulties with vector readministration. We have created new cell lines that allowed the isolation of more disabled adenovirus vectors that have both E1 and E4 deletions. Studies with murine models of liver-directed gene therapy indicated that the E1- and E4-deleted vector expresses fewer virus proteins and induces less apoptosis, leading to blunted host responses and an improved safety profile. The impact of the E4 deletion on the stability of vector expression was confounded by immune responses to the transgene product, which in this study was beta-galactosidase. When transgene responses were eliminated, the doubly deleted vector was substantially more stable in mouse liver than was the E1-deleted construct. These studies indicate that adenovirus vectors with both E1 and E4 deletions may have advantages in terms of safety and efficacy over first-generation constructs for liver-directed gene therapy.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=190991Documentos Relacionados
- Adeno-Associated Virus as a Vector for Liver-Directed Gene Therapy
- Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia.
- Liver-directed gene therapy: quantitative evaluation of promoter elements by using in vivo retroviral transduction.
- Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
- Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy.